Abstract：
The treatment landscape of gynecologic cancers has expanded in recent years to include targeted and immune-based therapies. These therapies often have ocular side effects not seen with conventional chemotherapies, some of which can cause significant visual impairment if not recognized in a timely fashion. Clinicians must know how to appropriately identify, mitigate, and treat these ocular adverse events. Management often involves working with an interdisciplinary team of eye specialists, and it is important to know when to refer patients for specialized care. Proactive identification of eye specialists, especially in rural and community settings where access to care can be limited, may be necessary. Here, we discuss the management of common ocular toxicities seen with novel anticancer agents used to treat gynecologic cancers.
摘要：
近年来，妇科癌症的治疗领域已经扩大到包括靶向和基于免疫的治疗。这些疗法通常具有常规化学疗法所没有的眼部副作用。如果不及时识别，其中一些可能会导致严重的视力障碍。临床医生必须知道如何正确识别，缓解,并治疗这些眼部不良事件。管理通常涉及与跨学科的眼科专家团队合作，重要的是要知道何时转诊患者进行专门护理。积极识别眼科专家，特别是在农村和社区环境中，获得护理的机会可能受到限制，可能是必要的。这里,我们讨论了用于治疗妇科癌症的新型抗癌药物对常见眼部毒性的管理。
